Literature DB >> 22725618

Pregabalin in clinical psychiatry and addiction: pros and cons.

Giovanni Martinotti.   

Abstract

Pregabalin acts as a presynaptic modulator of excitatory neurotransmitter release, binding to the α²-δ subunit protein of voltage-gated calcium channels. Pregabalin use is becoming widespread in the psychiatric scenario. Data are encouraging, with some good evidence for efficacy in anxious spectrum, benzodiazepine abuse/dependence, and alcoholism. The abuse potential, however, is an issue that should be taken into account, mostly in subjects at risk for developing substance/alcohol misuse.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22725618     DOI: 10.1517/13543784.2012.703179

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  13 in total

Review 1.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

2.  Pregabalin abuse and dependence in Germany: results from a database query.

Authors:  Maximilian Gahr; Roland W Freudenmann; Christoph Hiemke; Makus A Kölle; Carlos Schönfeldt-Lecuona
Journal:  Eur J Clin Pharmacol       Date:  2013-01-05       Impact factor: 2.953

3.  Misuse of the γ-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK.

Authors:  Vikas Kapil; Jody L Green; Marie-Claire Le Lait; David M Wood; Paul I Dargan
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

4.  Executive cognitive dysfunction and ADHD in cocaine dependence: searching for a common cognitive endophenotype for addictive disorders.

Authors:  Paulo Jannuzzi Cunha; Priscila Dib Gonçalves; Mariella Ometto; Bernardo Dos Santos; Sergio Nicastri; Geraldo F Busatto; Arthur Guerra de Andrade
Journal:  Front Psychiatry       Date:  2013-10-21       Impact factor: 4.157

Review 5.  Ventral Tegmental Area Afferents and Drug-Dependent Behaviors.

Authors:  Idaira Oliva; Matthew J Wanat
Journal:  Front Psychiatry       Date:  2016-03-07       Impact factor: 4.157

6.  The pattern of substance use disorder in the United Arab Emirates in 2015: results of a National Rehabilitation Centre cohort study.

Authors:  Hiba Alblooshi; Gary K Hulse; Ahmed El Kashef; Hanan Al Hashmi; Mansour Shawky; Hamad Al Ghaferi; Habiba Al Safar; Guan K Tay
Journal:  Subst Abuse Treat Prev Policy       Date:  2016-05-13

Review 7.  Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review.

Authors:  Rainer Freynhagen; Miroslav Backonja; Stephan Schug; Gavin Lyndon; Bruce Parsons; Stephen Watt; Regina Behar
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 8.  Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice.

Authors:  Bernardo Dell'Osso; Umberto Albert; Anna Rita Atti; Claudia Carmassi; Giuseppe Carrà; Fiammetta Cosci; Valeria Del Vecchio; Marco Di Nicola; Silvia Ferrari; Arianna Goracci; Felice Iasevoli; Mario Luciano; Giovanni Martinotti; Maria Giulia Nanni; Alessandra Nivoli; Federica Pinna; Nicola Poloni; Maurizio Pompili; Gaia Sampogna; Ilaria Tarricone; Sarah Tosato; Umberto Volpe; Andrea Fiorillo
Journal:  Neuropsychiatr Dis Treat       Date:  2015-07-30       Impact factor: 2.570

9.  Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting.

Authors:  Emilio Blanco Tarrio; Rafael Gálvez Mateos; Enric Zamorano Bayarri; Vanessa López Gómez; Maria Pérez Páramo
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

Review 10.  Targeting the glutamatergic system to treat pathological gambling: current evidence and future perspectives.

Authors:  Mauro Pettorruso; Luisa De Risio; Giovanni Martinotti; Marco Di Nicola; Filippo Ruggeri; Gianluigi Conte; Massimo Di Giannantonio; Luigi Janiri
Journal:  Biomed Res Int       Date:  2014-06-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.